| Abstrakt: |
1The influence of sulphasalazine (SASP) on the pharmacokinetics of low dose methotrexate (MTX) and the relation between pharmacokinetic variables and clinical response was studied in 15 patients with active rheumatoid arthritis despite >6 months of SASP treatment. 2SASP was stopped for 2 weeks. Thereafter a single oral dose of 7.5 mg MTX was administered after a standard breakfast. Blood was sampled initially every 30 min, thereafter hourly during 8 h. Urine was sampled every hour. Then 2000 mg SASP daily + 7.5 mg MTX weekly was given. After 4 weeks the same procedure was repeated supplemented with concomitant administration of 1000 mg SASP. Clinical measurements included Ritchie articular index, number of swollen joints, ESR and the disease activity score. Pharmacokinetic analysis was performed using a two- compartment model with first order absorption and lag time. Results are given as mean (s.d.). Paired t-test or signed rank test were applied in the statistical analysis. 3Pharmacokinetics of MTX without vs with SASP, means±s.d. were as follows: AUC: 673±179 vs 628±210 (95% confidence interval [CI] of the difference was −71 to 159) ng ml−1 h, MRT: 5.2±1.3 vs 5.2±1.1 (95% CI −0.4 to 0.4) h, t½,z: 4.3±1.1 vs 4.2±1.1 (95% CI −0.3 to 0.5) h, V / F: 59.3 ±29.3 vs 65.5±25.3 (95% -23.8 to 11.4) l, CL/ F: 12.3±5.0 vs 13.5±4.8 (95% CI −4.5 to 2.3) l h−1. CLR/ F: 6.2±1.3 vs 6.3±2.1 (95% CI −1.3 to 1.1) l h−1. All P values were ≥0.3. 4A weak correlation existed between the change of ESR and the MRT, the t½,z and the V / F (Spearman correlation coefficients of 0.43, 0.50 and 0.50 respectively, 0.05< P<0.1). 5There is no significant influence of chronic SASP administration on the pharmacokinetics of MTX or vice versa. Of the clinical variables, only the ESR correlated consistently with some pharmacokinetic variables of MTX. [ABSTRACT FROM AUTHOR] |
Plný text